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ABSTRACT 
Background & Aims: Recruitment of gut-derived memory T cells to the liver 
is believed to drive hepatic inflammation in primary sclerosing cholangitis 
(PSC). However, whether gut-infiltrating and liver-infiltrating T cells share T-
cell receptors (TCRs) and antigenic specificities is unknown. We used paired 
gut and liver samples from PSC patients with concurrent inflammatory bowel 
disease (PSC-IBD), and normal tissue samples from colon cancer controls, to 
assess potential T-cell clonotype overlap between the two compartments. 
Methods: High-throughput sequencing of TCRβ repertoires was applied on 
matched colon, liver and blood samples from patients with PSC-IBD (n=10), 
and on paired tumor-adjacent normal gut and liver tissue samples from colon 
cancer patients (n=10). 
Results: An average of 9.7% (range: 4.7–19.9%) memory T-cell clonotypes 
overlapped in paired PSC-IBD affected gut and liver samples, after excluding 
clonotypes present at similar frequencies in blood. Shared clonotypes 
constituted on average 16.0% (range: 8.7–32.6%) and 15.0% (range: 5.9–
26.3%) of the liver and gut memory T cells, respectively. A significantly higher 
overlap was observed between paired PSC-IBD affected samples (8.7%, 
p=0.0007) compared to paired normal gut and liver samples (3.6%), after 
downsampling to equal number of reads. 
Conclusion: Memory T cells of common clonal origin were detected in paired 
gut and liver samples of patients with PSC-IBD. Our data indicate that this is 
related to PSC-IBD pathogenesis, suggesting that memory T cells driven by 
shared antigens are present in the gut and liver of PSC-IBD patients. Our 
findings support efforts to therapeutically target memory T-cell recruitment in 
PSC-IBD.  
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INTRODUCTION 
Primary sclerosing cholangitis (PSC) is a chronic inflammatory liver disease of 
unknown etiology. Effective disease-modifying medical treatment remains 
elusive. PSC is strongly associated with inflammatory bowel disease (IBD), 
with 60–80% of PSC patients having coexistent IBD [1]. The mechanism 
responsible for this association is unclear, and patients may develop PSC 
after total colectomy, or IBD may appear after liver transplantation [2, 3]. A 
number of hypothesized pathways to liver injury have been suggested for 
PSC [1], and a variety of proposed phase II clinical trials target individual 
biological pathways [4].  
 
Effector T cells homing to the intestine express high levels of α4β7 integrin 
and CCR9 chemokine receptor, which bind to the endothelial adhesion 
molecule MAdCAM-1 and CCL25 chemokine, respectively [5, 6]. It has been 
reported that there is an aberrant expression of the gut-specific molecules 
MAdCAM-1 and CCL25 in human PSC livers [7-9] and that α4β7+CCR9+ 
effector memory T cells constitute approximately 20% of the liver-infiltrating 
lymphocytes in PSC patients [7]. These findings have led to the hypothesis 
that gut-derived memory T cells migrate to the liver and, upon recognition of 
an antigen, expand and promote inflammation [10]. In agreement, studies in 
mice show that T cells primed in the gut-associated lymphoid tissue by 
ovalbumin migrate to the liver and cause cholangitis when recognizing the 
same antigen on bile ducts [11]. In human PSC there has so far been no 
evidence for gut-infiltrating and liver-infiltrating T cells being clonally related. 
Using paired gut and liver tissue from PSC patients with concurrent IBD 
(PSC-IBD), we assessed whether gut-infiltrating and liver-infiltrating T cells 
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carry the same T-cell receptors (TCRs), i.e. are clonally related and able to 
recognize the same antigen(s) in the PSC-IBD affected gut and liver. We 
further investigated whether clonally related T cells are present in paired 
tumor-adjacent normal gut and liver tissue sampled from colon cancer 
patients.  
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MATERIALS AND METHODS 
Study populations 
Matched fresh-frozen explanted whole liver tissue (50–60mg), colonic 
biopsies from the ascending colon (1–5mg) and EDTA anti-coagulated 
peripheral blood (6ml) from Norwegian patients with PCS-IBD (n=10) were 
used in this study (see Table 1 and Supplementary Table 1 for clinical 
patient characteristics at time of each sample collection). PSC was diagnosed 
based on accepted criteria with typical findings of bile duct irregularities on 
cholangiography [12]. The diagnosis and classification of IBD was based on 
commonly accepted clinical, endoscopic and histopathologic criteria [13]. One 
patient was diagnosed with Crohn’s disease, while the remaining nine patients 
had ulcerative colitis. Colonic biopsies had been collected during routine 
colonoscopy, and active colonic inflammation had been graded according to 
the Mayo UC endoscopic subscore [14, 15]. Blood samples had been 
collected at the same date as the colonic biopsies. The median time from the 
colonoscopy and blood sampling to liver transplantation was 3.5 years (range 
0.6–7.3 years) (Supplementary Table 1). The study size was determined 
based on the number of available matched colonic biopsies, blood and liver 
samples from patients with PSC-IBD.  
 
Paired tumor-adjacent normal gut and liver tissue were sampled in 
Birmingham, UK from patients with colon cancer that developed colorectal 
metastasis in their liver (n=10; see Table 1 and Supplementary Table 2 for 
clinical patient characteristics at time of each sample collection). The normal 
tissue was available as formalin-fixed, paraffin-embedded (FFPE) material.  
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Ethics 
The study was performed in accordance with the Declaration of Helsinki. The 
study was approved by local research ethics committees (2012-286 and 
15/NW/0079), and written informed consent was obtained from all patients. 
 
High-throughput sequencing and analysis of the TCRβ chain 
Genomic DNA (gDNA) was extracted from fresh-frozen PSC-IBD affected 
colonic biopsies and explanted whole liver tissue using the AllPrep DNA RNA 
micro and mini kit following the manufacturer’s instruction (Qiagen, Valencia, 
CA, USA), respectively. Peripheral blood gDNA was extracted using a 
modified salting-out technique [16]. gDNA from FFPE normal gut and liver 
tissue was extracted using the QIAamp DNA FFPE tissue kit following the 
manufacturer’s instruction (Qiagen). The rearranged TCRβ complementarity-
determining region 3 (CDR3) was amplified from gDNA using a multiplex PCR 
and sequenced by Adaptive Biotechnologies (Seattle, WA, USA) using their 
ImmunoSEQ assay [17, 18]. Gut and liver TCRβ repertoires were sequenced 
at survey resolution, while peripheral blood TCRβ repertoires were sequenced 
at deep level resolution, according to company’s guidelines for samples 
derived from non-lymphoid tissues and whole blood, respectively. PCR and 
sequencing errors were removed, and for each unique sequence, the 
nucleotide and predicted amino acid sequence, V (variable), D (diversity) and 
J (joining) genes and the number of sequencing reads were determined. The 
data was further sorted to exclude any sequence with an out-of-frame 
rearrangement or a stop codon in the CDR3, and the frequency was 
determined for each of the remaining productive unique sequences  
(nucleotide clonotypes).  
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Data were analysed using the ImmunoSEQ Analyzer 
(http://www.adaptivebiotech.com/immunoseq/analyzer), R statistical software 
environment (version 3.2.3, https://www.R-project.org/) and general 
bioinformatics strategies. T-cell clonality was calculated as 1 - (Shannon’s 
Entropy)/log2(number of nucleotide clonotypes). A clonality score of 1 
indicates a monoclonal sample, whereas a score of 0 indicates a maximally 
diverse sample. The number of productive gene rearrangements was 
calculated as (the number of sequencing reads)/(amplification factor). The 
amplification factor of each sample was determined using spiked-in synthetic 
molecules. Richness was calculated as (number of nucleotide 
clonotypes)/(number of productive gene rearrangements) and percent T cells 
was calculated as (number of productive gene rearrangements)/(number of 
diploid genomes). Considering the mass of a diploid genome is approximately 
6.5pg, the number of diploid genomes was calculated using information on the 
mass of reaction template (the amount of gDNA used per sample). Nucleotide 
clonotype overlap was calculated as [(number of nucleotide clonotypes found 
in both liver and gut X 2)/(total number of nucleotide clonotypes in the liver 
and gut sample)] X 100. Jaccard index was calculated using the ‘sets’ 
package [19] (version 1.0.16) in R as (number of nucleotide clonotypes found 
in both liver and gut)/((total number of nucleotide clonotypes in the liver and 
gut sample)-(the number of nucleotide clonotypes found in both liver and 
gut)). The overlap coefficient was calculated as (number of nucleotide 
clonotypes found in both liver and gut)/(total number of nucleotide clonotypes 
for the smallest patient sample). The proportion of the liver and gut memory T 
cells carrying overlapping gut-liver memory clonotypes was calculated as 
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(number of sequencing reads for overlapping gut-liver memory 
clonotypes)/(total number of sequencing reads for memory TCRβ repertoire) 
X 100. 'Memory TCRβ repertoire’ denotes here the gut or liver nucleotide 
clonotypes found at a frequency of >0.01%, and which were not detected in 
the matched blood sample at a frequency of >0.01%. For the comparison of 
clonotype overlap in paired PSC-IBD affected tissue samples and paired 
normal gut and liver tissue, each sample was downsampled to 20,264 reads.  
 
HLA typing 
From peripheral blood gDNA of patients with PSC-IBD, HLA-B and HLA-
DRB1 were amplified and prepared for sequencing using the NGSgo workflow 
(GenDX, Utrecht, Netherlands). High-throughput sequencing of the samples 
was carried out on a MiSEQ instrument (Illumina, San Diego, CA, USA) by the 
Norwegian Sequencing Centre (Oslo, Norway), and the alleles were assigned 
using the NGSengine 1.7.0 software (GenDX). 
 
Statistical analyses 
All values are presented as mean ± SEM unless stated otherwise. Wilcoxon 
Signed Rank Test was used when comparing V and J gene usage of 
overlapping gut-liver memory clonotypes and the non-overlapping gut or liver 
memory clonotypes, while Mann-Whitney U test was used when comparing V 
and J gene usage of total gut and liver memory TCRβ repertoires, when 
comparing clonotype overlap in paired normal gut and liver tissue and paired 
PSC-IBD affected gut and liver tissue, when comparing V and J gene usage 
of nucleotide clonotypes in normal and PSC-IBD affected gut and liver tissues 
and to compare clonality scores. When comparing V and J gene usage, we 
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adjusted the p-values for the number of V and J genes tested using 
Benjamini-Hochberg procedure. A p-value less than 0.05 was regarded as 
statistically significant. Statistical analyses were performed using IBM SPSS 
Statistics 22 software (IBM, Armonk, NY, USA) and R statistical software 
environment (version 3.2.3, https://www.R-project.org/), and graphs were 
made using Prism 6.0 (GraphPad Software, La Jolla, CA, USA). 
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RESULTS 
Gut and liver memory T cells of common clonal origin are detected in patients 
with PSC-IBD 
We sequenced the TCR repertoires of liver, gut and blood-derived T cells 
from 10 patients with PSC-IBD (Table 1 and Supplementary Table 1). A 
detailed description of the TCR sequence data is given in Supplementary 
Table 3. The HLA type of each patient with PSC-IBD was also determined; all 
patients had at least one HLA-DRB1 PSC risk allele – HLA-DRB1*03:01, -
DRB1*13:01 and/or -DRB1*15:01 – and five patients were either 
heterozygous or homozygous for the HLA-B*08:01 PSC risk allele 
(Supplementary Table 1).  
 
In the antigen-experienced memory T-cell repertoire, a rearranged TCRβ 
nucleotide sequence (nucleotide clonotype) is generally unique to each T-cell 
clone [20, 21]. Thus, to investigate whether gut-infiltrating and liver-infiltrating 
T cells in human PSC-IBD are clonally related, we studied the overlap of 
nucleotide clonotypes in paired gut and liver samples from patients with PSC-
IBD. An average clonotype overlap ranging from 9.1% (range: 6.4–13.5%) for 
the total TCRβ repertoire to 16.6% (range: 4.0–32.9%) for the nucleotide 
clonotypes present at frequencies greater than 0.1% was detected (Fig. 1A).  
 
Naïve T cells can share the same TCRβ nucleotide sequence but have 
different TCRα sequences [20]. Therefore, in order to omit TCRβ nucleotide 
clonotypes that might originate from naïve T cells [22-25] and to focus on the 
more expanded clonotypes (here designated as ‘memory TCRβ repertoire’) 
we used a clonotype frequency of 0.01% as a threshold for further analysis. 
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Moreover, as data from circulating T cells might contaminate the TCRβ 
repertoires of gut- and liver-infiltrating T cells, any liver or gut nucleotide 
clonotype that was also detected in the matched blood sample at frequencies 
greater than 0.01% was excluded from the analysis. On average, an overlap 
of 9.7% (range: 4.7–19.9%) nucleotide clonotypes in the gut and liver memory 
TCRβ repertoire of each PSC-IBD patient was detected (Fig. 1B).  
 
The overlapping nucleotide clonotypes of paired gut and liver memory TCRβ 
repertoires (‘overlapping gut-liver memory clonotypes’), their encoded amino 
acid clonotypes, V and J genes and frequencies are given in Supplementary 
Table 4. A similar V and J gene usage of the overlapping gut-liver memory 
clonotypes and the gut and liver memory TCRβ repertoires was observed 
(Supplementary Fig. 1–6 and Supplementary Table 5–6). An average of 
16.0% (range: 8.7–32.6%) of liver memory T cells and 15.0% (range: 5.9–
26.3%) of gut memory T cells carried overlapping gut-liver memory clonotypes 
(Fig. 2). Among the overlapping gut-liver memory clonotypes identified in this 
study, we detected amino acid clonotypes previously reported to recognize 
epitopes of polyomavirus BK (CASSLGGSNQPQHF), cytomegalovirus 
(CASSPSRNTEAFF, CASSPQRNTEAFF) and Epstein-Barr virus 
(CASSQSPGGTQYF, CSARDRVGNGYTF, CASSSLNTEAFF) [26-31]. Our 
data confirm the presence of T cells of common clonal origin in the liver and 
gut of patients with PSC-IBD. 
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The overlap of TCR repertoires in PSC-IBD affected gut and liver tissue is 
significantly higher than in normal gut and liver tissue 
Next, we investigated the overlap of nucleotide clonotypes in paired normal 
gut and liver tissue sampled from 10 patients with colon cancer that 
developed colorectal metastasis in their liver (Table 1 and Supplementary 
Table 2).  
 
The average number of sequencing reads sampled from normal liver and gut 
samples were 58,159 reads (range: 2,452–158,151 reads) and 80,265 reads 
(range: 2,799–391,195), respectively (Supplementary Table 7). In 
comparison, the average number of sequencing reads sampled from PSC-
IBD affected liver and gut samples were 810,609 reads (range: 171,374–
1,957,860 reads) and 569,428 reads (range: 291,815–858,580 reads), 
respectively (Supplementary Table 3). Since overlap analyses are sensitive 
to differences in sample size, we normalized by downsampling the PSC-IBD 
affected tissue samples and normal tissue samples to the same number of 
reads [32]. Five colon cancer controls  (CNTR-1, CNTR-2, CNTR-4, CNTR-7 
and CNTR-8) were excluded from the overlap analyses due to the low read 
count of either their gut or liver sample. Consequently, we randomly picked 
20,264 reads (i.e. the size of the smallest remaining sample) from the total 
repertoire of each PSC-IBD sample and remaining control sample. An 
average overlap of 3.6% (range: 1.6–4.6%) nucleotide clonotypes was 
detected in the gut and liver TCR repertoires of paired normal tissue, 
whereas an average clonotype overlap of 8.7% (range: 5.3–11.9%) was 
detected for paired PSC-IBD affected gut and liver tissue (Fig. 3A). 
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Differences in V and J gene usage were observed between normal and PSC-
IBD affected gut and liver TCRβ repertoires (Supplementary Fig. 7). 
 
Despite having the same number of reads in each patient sample, there were 
approximately ten times the total number of nucleotide clonotypes in samples 
from patients with PSC-IBD compared to samples from colon cancer controls 
(Supplementary Table 8). Therefore, we further picked the 100 most 
abundant nucleotide clonotypes from each sample and repeated the 
clonotype overlap measurements. An average clonotype overlap of 3.8% 
(range: 1.0–6.0%) was observed for paired normal gut and liver tissue (Fig. 
3B). In comparison, an average clonotype overlap of 16.6% (range: 3.0–
28.0%) was detected for paired gut and liver samples from patients with PSC-
IBD. Additional overlap indices (i.e. Jaccard index and overlap coefficient) are 
given in Supplementary Table 8 and Supplementary Table 9. The random 
downsampling procedure and overlap measurements were repeated five 
times, with similar degree of overlap observed each time (data not shown). 
Taken together, these findings suggest that there is a significantly higher 
sharing of TCR repertoires between paired PSC-IBD affected gut and liver 
tissue compared to paired normal gut and liver tissue.  
 
PSC-associated amino acid clonotypes are present in Norwegian PSC 
patients  
We next investigated whether we could detect the eight previously reported 
PSC-associated amino acid clonotypes [17]. The PSC-associated amino acid 
clonotypes were present in up to 50% of the PSC-IBD liver samples, in up to 
40% of the PSC-IBD gut samples and in up to 90% of the PSC-IBD blood 
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samples (Table 2). The PSC-associated amino acid clonotypes that were 
detected in blood samples were found at lower frequencies compared to 
those encoded by identical nucleotide clonotypes in the matched gut or liver 
sample (Supplementary Table 10). We further detected two PSC-associated 
amino acid clonotypes (CASSDTSGGADTQYF, CASSPGQGEGYEQYF) in 
10% of the normal liver samples and one PSC-associated amino acid 
clonotype (CASSLGSGANVLTF) in 10% of the normal gut samples (Table 2 
and Supplementary Table 10). Two of the overlapping gut-liver memory 
clonotypes encoded previously reported PSC-associated amino acid 
clonotypes (CASSELAGGPETQYF, CASSPGQGEGYEQYF) 
(Supplementary Table 4). Collectively, the previously identified PSC-
associated amino acid clonotypes were also detected in the Norwegian PSC-
IBD study population. 
 
Clonal distribution of liver-, gut- and blood-derived T cells 
The clonal distribution of T cells from patients with PSC-IBD was evaluated. 
The nucleotide clonotypes detected at a frequency of >0.01% constituted on 
average 63.6% and 60.2% of the total liver and gut TCRβ repertoires, 
respectively (Fig. 4A). The majority of nucleotide clonotypes in the PSC-IBD 
affected gut and liver samples had a frequency within a range of 0.001–
0.01%, whereas an average of 86.4% of the nucleotide clonotypes detected in 
blood had a frequency of <0.001% (Fig. 4B). When assessing clonality, a 
measurement of T-cell diversity considering the variation of clonotype 
frequencies independent of sampling depth, similar scores for PSC-IBD 
affected liver (median 0.16, range 0.12–0.25), gut (median 0.15, range 0.08–
0.35) and blood (median 0.20, range 0.03-0.46) TCRβ repertoires were 
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observed (Fig. 4C). Similar clonality scores were likewise observed for normal 
liver (median 0.12, range 0.08–0.38) and gut (median 0.10, range 0.06–0.20) 
TCRβ repertoires (Supplementary Fig. 8). These data suggest that there is a 
similar T-cell diversity in PSC-IBD affected tissues and in peripheral blood. 
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DISCUSSION 
The present study is the first to examine the T-cell repertoires of paired liver 
and gut samples using high-throughput sequencing of the TCRβ chain. We 
demonstrate for the first time the presence of human gut and liver memory T 
cells of common clonal origin. We observed a significantly higher sharing of 
TCRβ repertoires in paired PSC-IBD affected gut and liver samples than in 
paired tumor-adjacent normal gut and liver tissue, and further detected the 
previously reported PSC-associated amino acid clonotypes in the Norwegian 
population of PSC patients. 
 
Our study provides the first human-based evidence that gut and liver memory 
T cells of common clonal origin are present in PSC patients. An average of 
16% of liver memory T cells and 15% of gut memory T cells carried 
overlapping nucleotide clonotypes, suggesting that a high proportion of the 
memory T cell repertoire in gut and liver is able to recognize the same 
antigens or antigens that share sequence or structural similarities. Our data 
are compatible with the hypothesis that an enterohepatic migration of T cells 
contributes to the pathogenesis of PSC, as previously suggested based on 
the aberrant expression of gut-specific molecules, the endothelial adhesion 
molecule MAdCAM-1 and chemokine CCL25, and the presence of 
α4β7+CCR9+ effector memory T cells in the inflamed livers of PSC patients [7-
9]. The shared gut and liver TCRβ repertoires might also be the result of 
shared naïve T-cell clones and antigens occurring at both sites, which in the 
presence of shared HLA haplotypes led to activation and expansion of the 
same naïve T-cell clones in the gut and the liver. Nevertheless, the 
significantly higher sharing of TCRβ repertoires between paired PSC-IBD 
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affected tissues than between paired tumor-adjacent normal gut and liver 
tissue suggests that our findings are related to PSC-IBD pathogenesis.  
 
Previously, we had identified eight amino acid clonotypes that were present in 
30-40% of UK PSC livers (n=20) and absent from liver tissue sampled from 
patients with primary biliary cirrhosis (n=10) and alcoholic liver disease (n=10) 
[17]. In the current study, we detected these PSC-associated amino acid 
clonotypes in up to 50% of the liver samples and up to 40% of the gut 
samples from Norwegian patients with PSC-IBD.   
 
There are several constraints to be acknowledged in the present study. The 
availability of only fresh-frozen or FFPE gut and liver samples from patients 
with PSC-IBD and from colon cancer controls, respectively, did not allow us to 
sort the T cells prior to sequencing. The use of sorted T cell subsets might 
reveal more detailed information on the clonotype overlap between the two 
compartments, however this would require the isolation of cells at the time of 
each sample collection. We further acknowledge that differences in TCRβ 
repertoire overlap might exist across populations from different geographical 
origins, as the normal tissue samples and the PSC-IBD affected tissue were 
sampled in the UK and in Norway, respectively. Moreover, gDNA extracted 
from FFPE tissue is likely fragmented and this might have affected the 
number of sequencing reads retrieved from the colon cancer control samples, 
however fragmentation is unbiased and thus will not specifically affect 
particular nucleotide clonotypes. Finally, we acknowledge that the PSC-IBD 
affected liver samples and colonic biopsies used in our study represent only a 
small proportion of the diseased microenvironment. This, in addition to the 
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patchy nature of PSC disease, makes the task of identifying overlapping 
clonotypes in PSC-IBD challenging.  
 
The colonic biopsies and explanted livers were sampled from the ten patients 
with PSC-IBD over a time period of more than 7 years. Utilizing this rare 
collection of matched PSC-IBD samples and the highly sensitive high-
throughput sequencing approach, human gut- and liver-infiltrating T cells of 
common clonal origin could be identified for the first time. A similar study has 
not been previously feasible due to the constraints of older technologies and 
the limited access to matched material from PSC patients. We are unable to 
confirm whether the T cells were initially activated in the gut, liver or 
elsewhere. Sampling each tissue at multiple time points (ideally tracking 
clonotypes before the onset of disease) would have been required. This is, 
however, ethically inappropriate and thus impossible.  
 
In conclusion, we have detected the presence of previously reported PSC-
associated amino acid clonotypes in a Norwegian PSC-IBD study population, 
and provide the first evidence that gut and liver memory T cells of common 
clonal origin are present in patients with PSC-IBD. Our data suggest this is 
related to PSC-IBD pathogenesis, supporting the hypothesis that memory T 
cells with shared antigenic drivers are present in the gut and liver of PSC 
patients. This mechanism is likely to be biological important and represents a 
potential therapeutic target for patients with concurrent PSC and IBD. 
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Table 1. Characteristics of the study populations.  
Plus or minus values are mean ± standard deviation. 
a Mean INR values from 6 of 10 colon cancer patients at time of colectomy 
and liver resection 
b Mean ALT values from 8 and 9 of 10 colon cancer patients at time of 
colectomy and liver resection, respectively 
c Mean platelets values from 7 and 9 of 10 colon cancer patients at time of 
colectomy and liver resection, respectively 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; 
IBD, inflammatory bowel disease; INR, international normalized ratio; PSC, 
primary sclerosing cholangitis 
 
Characteristics 
PSC-IBD (n=10) Colon cancer control (n=10) 
at colonoscopy at liver transplantation at colectomy at liver resection 
Age, years 44 ± 11 47 ± 10 65 ± 10 65 ± 9 
Male sex, % 60 60 40 40 
Bilirubin, umol/L 25 ± 15 16 ± 10 11 ± 6 13 ± 10 
INR a 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.2 1.2 ± 0.2 
ALT, U/L b 190 ± 156 86 ± 79 70 ± 87 131 ± 84 
ALP, U/L 318 ± 259 231 ± 126 181 ± 105 96 ± 41 
Albumin, g/L 39 ± 6 40 ± 6 35 ± 10 30 ± 9 
Platelets, 10^9/L c 298 ± 101 293 ± 125 298 ± 104 215 ± 65 
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Table 2. Primary sclerosing cholangitis (PSC) associated amino acid 
clonotypes. The table shows the number of samples in which each of the 
previously reported PSC-associated amino acid clonotypes [17] was observed 
in Norwegian patients with concurrent PSC and inflammatory bowel disease 
(IBD) and in tumor-adjacent normal tissue of colon cancer patients from 
Birmingham, UK. 
 
PSC-associated 
amino acid 
clonotypes 
Number of Norwegian PSC-IBD Number of control 
liver 
samples, 
n=10 
gut 
samples, 
n=10 
blood 
samples, 
n=10 
liver 
samples, 
n=10 
gut 
samples, 
n=10 
CASSDTSGGADTQYF 1 0 2 1 0 
CASSELAGGPETQYF 1 4 3 0 0 
CASSEYSNQPQHF 1 1 3 0 0 
CASSFTGTDTQYF 0 1 3 0 0 
CASSGTSGGADTQYF  3 1 2 0 0 
CASSLGSGANVLTF 5 2 9 0 1 
CASSPGQGEGYEQYF 2 1 3 1 0 
CASSPPSYEQYF 1 2 8 0 0 
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Figure Legends  
 
Fig. 1. Clonotype overlap in paired gut and liver samples from patients 
with primary sclerosing cholangitis-inflammatory bowel disease. For 
each patient, a T-cell receptor beta repertoire overlap was calculated based 
on the number of nucleotide clonotypes found in both gut and liver. (A) Data 
show the overlap of gut and liver clonotypes according to their frequencies. 
(B) Data show each patient’s overlap of gut and liver nucleotide clonotypes 
found at a frequency of >0.01%. Excluded from the analysis was any gut or 
liver nucleotide clonotype that was also detected in the matched blood sample 
at a frequency of >0.01%. 
 
Fig. 2. Percentage of gut and liver memory T cells carrying overlapping 
gut-liver memory clonotypes in primary sclerosing cholangitis. Data 
show the proportion of each patient’s gut and liver memory T cells carrying 
clonotypes that are overlapping between gut and liver memory T-cell receptor 
beta (TCRβ) repertoires (‘overlapping gut-liver memory clonotypes’) 
calculated as (number of sequencing reads for overlapping gut-liver memory 
clonotypes)/(total number of sequencing reads for memory TCRβ repertoire) 
X 100. ‘Memory TCRβ repertoire’ denotes here the clonotypes found at a 
frequency of >0.01%, and which were not detected in the matched blood 
sample at a frequency of >0.01%. 
 
Fig. 3. Clonotype overlap in normal and primary sclerosing cholangitis-
inflammatory bowel disease (PSC-IBD) affected paired gut and liver 
tissue. For each colon cancer control (n=5) and PSC-IBD patient (n=10), a T-
cell receptor beta repertoire overlap was calculated based on the number of 
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nucleotide clonotypes found in both gut and liver sample. (A) Data show the 
overlap of gut and liver clonotypes in controls and PSC-IBD patients. Each 
sample contained 20,264 reads. (B) Data show the overlap of gut and liver 
clonotypes amongst the 100 most abundant nucleotide clonotypes in samples 
with 20,264 reads from controls and PSC-IBD patients. (*p=0.0117, 
***p=0.0007). 
 
Fig. 4. Clonal distribution of liver-, gut- and blood-derived T cells. (A) 
Cumulative percentage distributions of nucleotide clonotypes at various 
frequencies in liver, gut and blood T-cell receptor beta (TCRβ) repertoires of 
primary sclerosing cholangis-inflammatory bowel disease (PSC-IBD) patients. 
(B) Frequency distributions of the liver-, gut- and blood-derived nucleotide 
clonotypes of PSC-IBD patients. (C) Data show the clonality of liver, gut and 
blood TCRβ repertoires of PSC-IBD patients. Data points represent the 
clonality score of each patient’s sample, and the horizontal lines represent the 
median of each group. Liver versus gut p=0.353; liver versus blood p=0.739; 
gut versus blood p=0.684. 
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